Labcorp and its Specialty Testing Group, a fully integrated portfolio of specialty and esoteric testing laboratories.

Lipid-associated Sialic Acid (LASA)

CPT: 84275
Updated on 02/26/2021
Print Share


  • LASA
  • Lipid-bound Sialic Acid

Special Instructions

Values obtained with different assay methods should not be used interchangeably in serial testing. It is recommended that only one assay method be used consistently to monitor each patient's course of therapy. This procedure does not provide serial monitoring; it is intended for one-time use only. If serial monitoring is required, please use the serial monitoring number 480129 to order.

Expected Turnaround Time

4 - 7 days

Related Information

Related Documents

Specimen Requirements


Serum or plasma


2 mL

Minimum Volume

0.1 mL


Red-top tube, gel-barrier tube, or lavender-top (EDTA) tube


If tube other than a gel-barrier tube is used, transfer separated serum or plasma to a plastic transport tube.

Storage Instructions

Room temperature

Stability Requirements



Room temperature

14 days


14 days


14 days

Freeze/thaw cycles

Stable x3

Test Details


LASA is a useful adjunct in the management of a variety of malignancies. It is generally used in conjunction with other tumor markers.


This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the Food and Drug Administration.



Reference Interval

8 - 23 mg/dL

*Reference interval has been verified for all age groups including pediatrics (birth to 18 years) and geriatrics.

8 - 23 mg/dL


8 - 23 mg/dL

*Reference interval has been verified for all age groups including pediatrics (birth to 18 years) and geriatrics.

Additional Information

Elevations in blood LASA levels have been reported in patients with mammary (63%), gastroenteric (65%), pulmonary (79%), and ovarian (94%) neoplasms as well as those with leukemia (86%), lymphoma (87%), melanoma (84%), sarcoma (97%), and Hodgkin disease (91%). LASA levels can also be elevated in patients with certain benign diseases, including inflammatory disorders. Thus, like carcinoembryonic antigen (CEA), the assay for LASA does not have the specificity or sensitivity necessary for cancer detection. However, recent studies have suggested that LASA levels may be useful in monitoring the course of therapy and detecting disease recurrence in certain cancer patients. In patients with mammary, ovarian, or colorectal neoplasms, a correlation has been found between LASA concentrations and therapeutic responses. Measurement of pre- and post-treatment LASA levels is advocated for determining a baseline for therapeutic monitoring. The combination of LASA and CEA measurements in patients with mammary, colorectal, or pulmonary cancer, and LASA and cancer antigen 125 (CA 125) measurements in those with ovarian cancer may improve the accuracy of assessing therapeutic responses. Preliminary studies have demonstrated that LASA concentrations are indicative of disease status in patients with leukemia, lymphoma, or cancer of the breast, ovary, or colorectum.


Bhargava AK, O'Donnell AM, Birl T, et al. Plasma lipid-bound sialic acid (LSA) in cancer and noncancer patients. Clin Chem. 1984; 30:940, 36th National Meeting of the American Association for Clinical Chemistry July 29−August 3, 1984, Washington, DC.
Dnistrian AM, Schwartz MK. Lipid-associated sialic acid. Clin Chem News. 1985; 11:14.
Dnistrian AM, Schwartz MK. Lipid-bound sialic acid as a tumor marker. Ann Clin Lab Sci. 1983; 13(2):137-142. 6859805
Dnistrian AM, Schwartz MK. Plasma lipid-bound sialic acid and carcinoembryonic antigen in cancer patients. Clin Chem. 1981 Oct; 27(10):1737-1739. 7285326
Dnistrian AM, Smith C, Schwartz D, et al. Lipid-bound sialic acid as a marker in lung cancer. Clin Chem. 1985; 31:982, 37th National Meeting of the American Association for Clinical Chemistry July 32−July 26, 1985, Atlanta, Ga.
Dunzendorfer U, Katopodis N, Dnistrian AM, Stock CC, Schwartz MK, Whitmore WF Jr. Plasma lipid bound sialic acid in patients with prostate and bladder cancer. Invest Urol. 1981 Nov; 19(3):194-196. 7298291
Dwivedi C, Dixit M, Hardy, et al. Plasma sialyltransferase, total sialic acid and lipid-bound sialic acid as tumor markers. Clin Chem. 1985; 31:983, 37th National Meeting of the American Association for Clinical Chemistry July 21−July 26, 1985, Atlanta, Ga.
Erbil KM, Jones JD, Klee GG. Use and limitations of serum total and lipid-bound sialic acid concentrations as markers for colorectal cancer. Cancer. 1985; 55(2):404-409. 3965096
Horgan IE. Total and lipid-bound sialic acid levels in sera from patients with cancer. Clin Chim Acta. 1982; 118(2-3):327-331. 7055991
Katopodis N, Hirshaut Y, Geller NL, et al. Lipid-associated sialic acid test for detection of human cancer. Cancer Res. 1982; 42(12):5270-5275. 7139630
Katopodis N, Stock CC. Improved method to determine lipid-bound sialic acid in plasma or serum. Res Commun Chem Pathol Pharmacol. 1980; 30(1):171-180. 7433766
Khanderia U, Keller JH, Grossman HB, et al. Serum sialic acid is a biological marker for malignant disease. J Surg Oncol. 1983; 23(3):163-166. 6865437


Order Code Order Code Name Order Loinc Result Code Result Code Name UofM Result LOINC
100313 Lipid-associated Sialic Acid 2943-9 100313 Lipid-associated Sialic Acid mg/dL 2943-9

For Providers

Please login to order a test

Order a Test

© 2020 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.

CPT Statement/Profile Statement

The LOINC® codes are copyright © 1994-2020, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at Additional information regarding LOINC® codes can be found at, including the LOINC Manual, which can be downloaded at